Fagundo-Sierra R, Cerros-Santos MA, Pérez-Jáuregui J, García-López ES, Mata-Rocha M, Andrade-Almaraz V

Language: Spanish
References: 34
Page: 94-102
PDF size: 122.81 Kb.

ABSTRACT

The BD Phoenix Automated Microbiology System (BD Diagnostics, Sparks, MD) allows for antimicrobial sensitivity testing and Extended-Spectrum Β-Lactamases (ESBL) confirmation in a single test panel for faster results in aiding physicians in treating patients with a lesser number therapeutic failures. The aim of this study was to assess the accuracy of the Phoenix system for the detection of ESBL in Escherichia coli and Klebsiella pneumoniae clinical isolates. Six hundred and six ESBL clinical isolates of E. coli and K. pneumoniae obtained from urine samples at the Carpermor Microbiology Laboratory detected by the Phoenix system for ESBL where studied. Agar disk diffusion phenotypic confirmatory tests performed following the Clinical Laboratory Standard Institute (CLSI) guidelines, and molecular detection done using the polymerase chain reaction (PCR) for the bla_TEM and bla_SHV genes where used like reference methods. Laboratory detection of ESBL avoided 257 false susceptible results that could represent therapeutic failures in the end. The strains studied showed good susceptible only to imipenem, amikacin and nitrofurantoin. Of the strains confirmed using Phoenix, 589 (97%) were positive in the agar diffusion test. In 13 of the 17 negative strains, TEM or SHV enzymes were detected. In 4 strains (1%), no ESBL were detected using either method. These results indicate that Phoenix is 99% sensitive for ESBL detection in E. coli and K. pneumoniae clinical isolates.

REFERENCES

1. Jacoby G, Munoz S. The new b-lactamases. N Engl J Med. 2005; 352: 386-91.

2. Mattar S, Martínez P. Emergencia de la resistencia antibiótica debida a las b-lactamasas de espectro extendido (BLEE): detección, impacto clínico y epidemiológico. Infectio. 2007; 11: 23-35.

3. Mendes C, Rossi A, Prado V, Zurita J, Robledo J, Guzman M, et al. Comparative evaluation of the susceptibility to the antimicrobials of Escherichia coli, Klebsiella pneumoniae, Salmonella and Shigella isolates from clinical specimens in Latin-America. The Resistent Group summaries of the Infectious Diseases Society of America (IDSA) 37 Annual Meeting Philadelphia, PA; 1999. p. 57.

4. Schwaber M, Navon S, Kaye K, Ben R, Schwartz D, Cameli Y. Clinical and economic impact of bacteremia with extended-spectrum-b-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006; 50: 1257-62.

5. Silva J, Gatica R, Aguilar C, Becerra Z, Garza-Ramos U, Velázquez M, et al. Outbreak of infection with extended-spectrum b-lactamase-producing Klebsiella pneumoniae in a Mexican hospital. J Clin Microbiol. 2001; 39: 3193-6.

6. Andrade V, Silva J. Caracterización de Klebsiella pneumoniae productora de la b-lactamasa SHV-5, en una unidad de cuidados intensivos. Salud Pública Mex. 2004; 46: 524-8.

7. Miranda G, Castro N, Leaños B, Valenzuela A, Garza-Ramos U, Rojas T, et al. Clonal and horizontal dissemination of Klebsiella pneumoniae expressing SHV-5 extended-spectrum b-lactamase in a Mexican pediatric hospital. J Clin Microbiol. 2004; 42: 30-5.

8. Silva-Sánchez J, Garza-Ramoz U, Sánchez A, Rojas T, Reyna F, Carrillo B. b-lactamasas en enterobacterias como principal mecanismo de resistencia a b-lactámicos. Rev Latinoam Microbiol. 2006; 48: 105-12.

9. Silva J, Aguilar C, Ayala G, Estrada M, Garza R, Lara L, et al. TLA-1, a new plasmid-mediated extended-spectrum b-lactamase from Escherichia coli. Antimicrob Agents Chemother. 2000; 44: 997-1003.

10. Clinical and Laboratory Standard Institute. CLSI. Performance standards for antimicrobial susceptibility testing; Seventeenth informational supplement. 2008; 28(1): M100-S18.

11. Jalier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer b-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988; 10: 67-78.

12. Jacoby G, Walsh K, Walter V. Identification of Extended-Spectrum, AmpC, and carbapenem-hydrolyzing b-lactamases in Escherichia coli and Klebsiella pneumoniae by disk tests. J Clin Microbiol. 2006; 44: 1971-.

13. Song W, Bae K, Lee YN, Lee CH, Lee S, Jeong S. Detection of extended-spectrum b-lactamases by using boronic acid as an AmpC b-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J Clin Microbiol. 2007; 45: 1180-4.

14. Fagundo SR, Cerros MA, Pérez-Jáuregui J. Evaluación del instrumento automatizado Phoenix en la identificación y antibiograma de bacterias de origen clínico. Bioquimia. 2007; 32: 39-48.

15. Isenberg HD. Clinical Microbiology Procedures Handbook, Vol. 1. 2nd ed. Washington, DC: American Society for Microbiology; 2004.

16. BD Phoenix System User´s Manual®. Copyright Becton, Dickinson and Company, 2004-2005.

17. Clinical and Laboratory Standard Institute. CLSI. Performance standards for antimicrobial disk susceptibility test; approved standard-ninth edition. 2006; 26: M2-A9.

18. Paterson D, Bonomo R. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18: 657-86.

19. Mroczkowska JE, Barlow M. Fitness trade-offs in blaTEM evolution. Antimicrob Agents Chemother. 2008; 52: 2340-5.

20. Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ, Navon-Venezia S. CTX-M-2 and new CTX-M-39 enzyme are the major Extended-Spectrum Beta-Lactamases in multiple Escherichia coli clones isolated in Tel Aviv, Israel. Antimicrob Agents Chemother. 2005; 49: 4745-50.

21. Schlesinger J, Navon-Venezia S, Chmelnitsky I, Hammer-Münz O, Leavitt A, Gold HS, et al. Extended-Spectrum Beta-Lactamases among enterobacter isolates obtained in Tel Aviv, Israel. Antimicrob Agents Chemother. 2005; 49: 1150-6.

22. Jonathan N. [Letter]. Screening for Extended-Spectrum Beta-Lactamase-producing pathogenic enterobacteria in district general hospitals. J Clin Microbiol. 2005; 43: 1488-90.

23. Doi Y, Adams J, O´Keefe A, Quereshi Z, Ewan L, Paterson DL. Community-acquired Extended-Spectrum b-Lactamase producers, United States. Emerging Inf Dis. 2007; 13: 1121-3.

24. Andrade V, Bustamante A. Prevalencia de Escherichia coli productoras de BLEE en infecciones de vías urinarias en pacientes pediátricos de la comunidad. Memorias. XXXII Congreso Nacional de Infectología y Microbiología Clínica; 2006. p. 32.

25. Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by Extended-Spectrum Beta-Lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004; 42: 1089-94.

26. Brunton LL, Lazo JS, Parker KI. Goodman & Gilman’s. The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill. 2006.

27. Karlowsky JA, Hoban DJ, DeCorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American urinary tract infection collaborative alliance-quinolone resistance study. Antimicrob Agents Chemother. 2006;50: 2251-4.

28. Sinha M, Srinivasa H. Mechanisms of resistance to carbapenems in meropenem- resistant Acinetobacter isolates from clinical samples. Indian J Med Microbiol. 2007; 25: 121-5.

29. Suarez CJ, Kattan JN, Guzman AM, Villegas MV. Mecanismos de resistencia a carbapenems en P. aeruginosa, Acinetobacter y Enterobacteriaceae y estrategias para su prevención y control. Infectio 2006; 10: 85-93

30. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. The sentry participants group (Latin America). SENTRY Antimicrobial Surveillance Program Report: Latin American and Brazilian results for 1997 through 2001. Braz J Infect Dis. 2004; 8: 25-79.

31. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999; 29: 745-58.

32. Sanguinetti M, Posteraro B, Spanu T, Ciccaglione D, Romano L, Fiori B, et al. Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum b-lactamases detection method. J Clin Microbiol. 2003; 41: 1463-8.

33. Wiegand I, Geiss H, Mack D, Stürenburg E, Seifert H. Detection of Extended-Spectrum-Beta-Lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J Clin Microbiol. 2007; 45: 1167-74.

34. Thomson K, Cornish N, Hong S, Hemrick K, Herdt C, Moland E. Comparison of Phoenix and Vitek 2 extended-spectrum-b-lactamase detection tests analysis of Escherichia coli and Klebsiella isolates with well-characterized b-lactamases. J Clin Microbiol. 2007; 45: 2380-4.